Podcasts about Medtronic

This conversation traces Dragonfly from an idea “in the back of a cab” to a clinically focused cholangioscopy platform that rotates through the biopsy channel for predictable, millimeter-level control. We delve into the mechanics (≈1.7 mm channel supporting 1.5 mm forceps and 4.5 Fr EHL), exploring how the catheter's suppleness and internal rigidity enhance distal duct stability and device passability, and why micro-movements and neutral ergonomics are crucial for case efficiency. We map where cholangioscopy shifts the algorithm—medium/large stones, altered anatomy, tight distal duct work, and stricture evaluation with larger bites—and talk learning curve (~3–5 cases), setup tips, and the Medtronic distribution partnership. Finally: adoption math, fair-use evaluations despite contracting realities, and a look toward accessory innovation and AI-aided visualization. Key takeaways Rotation-first control → faster targeting, less wall fighting, better stability in tight anatomy. Larger working channel enables bigger biopsies and higher-energy lithotripsy. Aim for complete fragmentation in session one; repeat procedures should be the exception. Ergonomics: neutral hand position and micro-movements reduce fatigue. Practical adoption requires training support and a fair, multi-case evaluation window. Links Dragonfly Endoscopy: https://dragonflyendoscopy.com Medtronic: https://www.medtronic.com/en-us/healthcare-professionals/products/digestive-gastrointestinal/ercp-devices/dragonfly-pancreaticobiliary-system.html  

APAC stocks extended losses throughout the session following a similar lead from Wall Street, which had seen heavy losses on Monday. Overall newsflow in APAC hours was quiet, although tech stocks were among the laggards in the region.DXY traded flat for most of the session and eventually drifted lower before dipping under 99.50 despite quiet newsflow, but as haven FX (JPY and CHF) gained amid risk aversion. JGB futures saw limited movement at the short end while the long end continued to weaken, pushing the 20-year yield to its highest level since July 1999. Bitcoin saw deep losses and eventually fell under the USD 90,000 mark to levels last seen in April, whilst Ethereum fell under USD 3,000.European equity futures are indicative of a lower cash open, with the Euro Stoxx 50 future down 1.1% after cash closed 0.9% lower on Monday.Looking ahead, highlights include US ADP Weekly Estimate, US Factory Orders (Aug), US Durable Goods (Aug), and Japanese Trade Balance. Speakers include ECB's Elderson; BoE's Pill, Dhingra; Fed's Barr, Barkin. Earnings include Home Depot, Baidu, Medtronic, PDD; Imperial Brands, Diploma.Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In Part 3 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, talks about his outlook for the future of his field, his views on how the industry and clinicians can collaborate more effectively and the healthcare changes he is most excited about. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold

After 14 years of managing Type 1 Diabetes with multiple daily injections, Eoin has reached a crossroads, and for the first time, he's seriously considering switching to an insulin pump.In this episode, he opens up about what's led him to this point. The routines that have worked for him, the frustrations that haven't, and why now feels like the right time to explore something new.If you've ever wondered what it's like to rethink your Diabetes management after years of doing things a certain way, or if you're also standing on the edge of a big diabetes decision this episode is for you.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

In Part 2 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business, Medtronic, shares how ECMO has transformed over the decades and explores how clinicians and industry can work together to support the most vulnerable patients in intensive care. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold

This week, Isabel is joined by Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, for a deep-dive into the evolution and future of ECMO, innovation in critical care and the realities of leading in the MedTech space. In Part 1 of the interview, Giuseppe talks about what attracted him to the medical device industry, what his day-to-day role involves and what advice he would give to anyone considering joining the MedTech sector. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold

“We learn traditionally that bone metastasis is terminal.” 一 Or is it? In this episode of the BackTable MSK podcast, host Dr. Jacob Fleming welcomes Dr. Francis Lee, a leading figure in orthopedic oncology, to discuss advancements in treating skeletal metastasis. Dr. Lee, the Wayne O. Southwick Professor from Yale and President-elect of the Musculoskeletal Tumor Society, shares his innovative AORIF (Ablation, Osteoplasty, Reinforcement and Internal Fixation) technique, which emphasizes collaboration between orthopedic oncologists and interventional radiologists. --- This podcast is supported by an educational grant from Medtronic. --- SYNPOSIS The conversation covers the complexities of bone metastasis, the biomechanics of skeletal ablation, and the importance of understanding bone-cancer interactions. Dr. Lee also shares insights from his translational research on cancer and bone dynamics, and emphasizes the need for continued interdisciplinary collaboration to drive forward minimally invasive treatments. --- TIMESTAMPS 00:00 - Introduction 01:39 - Crash Course: Orthopedic Oncology 10113:24 - The Important Role of Biomechanics20:10 - Dr Lee's Training and Interdisciplinary Collaboration28:13 - Intraoperative Imaging and Techniques in AORIF40:15 - Cannulated Screws for Access and Fixation 42:24 - Case Study: Sacral Insufficiency Fracture and Cement Injection44:17 - Understanding Cement Properties and Application46:45 - Case Study Series: Approach to Reconstruction57:58 - Decision Making in Complex Procedures01:08:40 - The Power of Bone Regeneration01:12:31 - Final Thoughts --- RESOURCES Dr. Francis Lee, MD, PhD, FAAOS, MBAhttps://medicine.yale.edu/profile/francis-lee/ Minimally Invasive Image-Guided Ablation, Osteoplasty, Reinforcement, and Internal Fixation (AORIF) for Osteolytic Lesions in the Pelvis and Periarticular Regions of Weight-Bearing Boneshttps://pubmed.ncbi.nlm.nih.gov/32139256/

In this episode of The Lebanese Physicians Podcast, co-hosts Dr. Khalil Diab and Dr. Hamad Ali sit down with Dr. Firas Mahdi, Partner at LEK Consulting in Singapore, to explore the intersection of strategy, technology, and innovation in healthcare across Asia and the Middle East. From his beginnings in clinical medicine at AUBMC to leadership roles at GE Healthcare, Medtronic, and now LEK, Dr. Mahdi shares a remarkable global journey spanning Lebanon, the Gulf, and Southeast Asia. We discuss: How Singapore's hybrid public–private healthcare model achieves world-class outcomes Lessons for Middle Eastern health systems in value-based care and operational excellence The evolving role of MedTech and AI in shaping the future of healthcare Building purpose-driven careers and navigating non-clinical paths in medicine A rich conversation about healthcare transformation, professional reinvention, and the future of global health strategy — where East truly meets Middle East.  

Join our champion program: mark@themomentumcompany.comAttend a Thriving Leader event: https://www.themomentumcompany.com/thrivingleader2026Instagram: @the.momentum.companyLinkedIn: /momentum-companyIn this episode, Mark Jewell sits down with veteran sales strategist Ken Pieh, a man with nearly four decades of experience transforming sales organizations—from Medtronic to fast-growing startups—through better incentive design.Ken shares real-world stories of how one small med-tech company went from $30 million to $200 million in revenue by overhauling its compensation model. He breaks down why most sales incentive plans unintentionally reward the wrong behaviors, and how to fix that before it costs you your best people.This is an episode every CEO, VP of Sales, and sales manager in agribusiness needs to hear. If your incentive plan doesn't align with your culture, goals, and leadership vision—you're probably burning money and morale.Key Takeaways:

In this inspiring conversation, Michelle sits down with Natalie de Minaur (Rowley), a Senior Product Manager at Medtronic, to explore what it really means to pivot with purpose. From moving countries with her family to redefining leadership without a title, Natalie shares the behind-the-scenes of navigating career, motherhood, and mindset with courage. Together, they dive into: Letting go of linear success Owning your self-worth and asking for what you're worth Reclaiming your energy and priorities Embracing "squiggly" paths and trusting your instincts If you've ever felt the nudge to do something different but fear held you back, this episode will speak directly to you.

In this episode of Let's Combinate: Drugs + Devices, host Subhi Saadeh speaks with Leonel Venegas, a seasoned quality and regulatory professional who has worked with global leaders including Alexion, Merck, Johnson & Johnson (Ethicon & Cordis), Amgen, and Medtronic.Leonel shares how integrating Good Laboratory Practices (GLP), Good Clinical Practices (GCP), and Good Pharmacovigilance Practices (GVP) is essential to successful combination-product development. He discusses his journey from chemist to regulatory-affairs expert, uncovering common disconnects between pharma and device cultures, and the critical role of design controls, risk management, and timelines.The conversation also explores GMP and process validation, IDE vs. IND pathways, the challenges of rare-disease programs, and how understanding the cost of quality can reshape testing strategies. Leonel closes by reflecting on becoming a Lean Six Sigma Black Belt and what continuous improvement really looks like in combination-product development.⏱ Timestamps00:00 – Welcome & Introduction00:52 – Integrating GLP, GCP & GMP02:22 – Challenges in Developing Combination Products04:02 – Device-Led Combination Products07:35 – Working with Rare Diseases09:58 – GMP & Process Validation15:08 – Clinical Trials: Drug vs Device19:22 – Cost of Quality & Six Sigma25:12 – Conclusion & Contact InformationLeonel Venegas is the Founder of Precision Regulatory Consulting LLC and an expert in quality and regulatory affairs with over two decades of experience across six global pharma and medtech leaders, including Alexion, Merck, Johnson & Johnson (Ethicon & Cordis), Amgen, and Medtronic.He is certified by ASQ as a CMQ/OE, CQE, CBA, and CSSBB, and holds an M.S. in Regulatory Affairs. Leonel specializes in combination products, medical devices, and IVDs, integrating GLP, GCP, GMP, and GVP principles into complex global development programs.

Host: Dr Sarah Saxena Speaker: Prof. Michael GrocottAs a fundamental aspect of the practice of anaesthesiology, haemodynamic monitoring is both routine and often elusive. Prof. Grocott has long been fascinated by this complex intervention. In this episode, he reflects, with Host Dr. Saxena, on the evolution of blood flow monitoring and how new technology might radically change how we manage haemodynamics in the OR.Supported by:Sintetica, BD and Medtronic

La Prof. María Trinidad Herreros, miembro de la Real Academia Nacional de Medicina, presenta la Alianza Carmen, formada por empresas e instituciones e impulsada por Organon, junto a Nutricia, Medtronic y Ogilvy, para conseguir que haya una equidad de género en los temas de salud.

Sarah Ptach, President and CEO of Canyon Labs, discusses her journey from professional sports and advertising to leading Canyon Labs, a company specializing in medical device and pharmaceutical testing. Inspired by her father's Parkinson's diagnosis, Sarah transitioned to healthcare to make a meaningful impact. She delves into her leadership philosophy, emphasizing the importance of trust, transparency, and collaboration in building a strong company culture. Sarah also highlights Canyon Labs' dedication to elevating industry standards and ensuring patient safety.    Guest links: https://canyonlabs.com/ | https://www.linkedin.com/in/sarahptach/  Charity supported: The Michael J. Fox Foundation for Parkinson's Research Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 067: Sarah Ptach [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I am super excited to introduce you to my guest, Sarah Ptach. Sarah is the President and CEO of Canyon Labs, a leading provider of medical device and pharmaceutical testing, consulting, and sterilization services. She joined the company during a critical ownership transition with a clear goal in mind: to raise the standard of service in the industry and build a true end-to-end solutions partner. Drawing on her background in packaging engineering and testing, Sarah focused on expanding beyond packaging alone to create a more integrated, accessible, and expert driven experience for clients. Sarah began her career in professional sports and advertising, but a desire to create more meaningful impact led her to the healthcare space after her father was diagnosed with Parkinson's disease. She went on to help grow and successfully exit a packaging firm before bringing her vision and leadership to Canyon Labs. In addition to her role at Canyon, she co-leads Kilmer Innovations and serves on the board of the Medical Device Packaging Technical Committee of the Institute of Packaging Professionals. She remains deeply committed to advancing healthcare through innovation, expertise, and strong partnerships. All right. Well, thank you so much for being here, Sarah. I'm so excited to welcome you to the show. [00:02:05] Sarah Ptach: Likewise. Thank you, Lindsey. I appreciate you having me. [00:02:08] Lindsey Dinneen: Of course. Well, I'd love if you would start off by telling us just a little bit about yourself, your background, and what led you to MedTech. [00:02:16] Sarah Ptach: Yeah. Thank you. So I'm Sarah Ptach. I'm the president of Canyon Labs. I have kind of an interesting story of getting into to medtech. I originally started my career actually in professional baseball. I was a contract negotiation person mainly for closing pitchers. And I ran track in college. I thought like, "oh, I wanna be in sports." And I like to say that's the most fun I never wanna have again. It was, it was a great start of a career. It teaches you a lot about negotiation, teaches you a lot about high stakes opportunities. But, you know, in the end it, it felt very kind of un unfulfilling in that perspective. And so I had kind of then taken that into to marketing for a pretty big ad agency in Chicago and hit the same thing. I felt like I was-- you know, now I was just selling people stuff that they didn't need instead of promoting people that, you know, that make a ton of money in the sports industry. And at the time my dad was diagnosed with Parkinson's disease and I wanted to feel like I was making a difference. So I, I went back and got my MBA and my whole goal of that was really to, to use my skills to, to do something that makes a difference in people's lives. So, I had reached out to a really small medical device company and it's " I'm willing to make no money as long as we, we have a difference in a change we can make in the world." And at the time that company couldn't hire me but I ended up getting introduced to another company through that that was in medical device packaging validation. And that was the first dip of medical device that I had. And that company's Packaging Compliance Labs. I was one of the first employees there and we grew that company until it sold a couple years ago. And through that, learned a ton about the medical device space. I kind of made it my personal mission beyond just my job to, to go try to participate in the industry as much as possible, push the status quo of things as much as possible, and really kind of learn where the testing realm or validation realm can make a difference in, in medical devices. And so after that, I was given the opportunity to step in and run and grow Canyon Labs. And Canyon is a whole platform. So for me, it was taking the packaging knowledge that, that I love so much and making that a full service offering. You know, I had always dabbled in sterilization or heard about Biocom, but never really gotten my hands on it. And to be able to be that full service solution with Canyon has not only been a awesome offering to, to give to our clients to really be able to go A to Z, everything from your regulatory to your microbiology, chemistry, packaging, bio comp, and toxicology. But also a good learning challenge for me. I thought that I was, you know, a pretty good packaging engineer and now learning chemistry and microbiology and toxicology, I'm like, "oh, wow. I'm definitely not as smart as I maybe thought I was originally," and I luckily have some amazingly intelligent individuals that, that work on our team, but it's, it's an awesome opportunity to, to not only get to help bring some life-changing medical solutions to market but also have a really good technical brain challenge every single day. [00:05:26] Lindsey Dinneen: Wow. Oh my goodness. I love that. And yes, I mean, sometimes I feel like actually, you know, not being the smartest person in the room is such a gift because then you get to talk to all these really cool people with really amazing experiences and learn. And I'm just one of those people who's constantly-- well, I'm curious all the time, so if I don't understand something, I'm like, "can you tell me more?" [00:05:48] Sarah Ptach: Yeah. No I love that. I completely agree. I think that the better that you can be at facilitating conversations, the, you know, the more successful your organization will be. And it, I really think as the leader of a company it's less about being the, you know, smartest person in the room and more about being the facilitator of that collaboration. [00:06:10] Lindsey Dinneen: Yeah. Yeah, absolutely. I love that. So, okay, so going back in time a little bit-- so, so I know you started off with professional sports, which is really cool. Like what a, what an interesting, unique opportunity and experience and you know, you'll maybe never want that particular brand of fun again, but. I still love that you got to do it. And so I'm curious though, was that always the sort of planning goal for you? Or when you were trying to think about career paths and all of that, younger, what were you envisioning? [00:06:39] Sarah Ptach: Yeah. I think I, I always envisioned myself as a leader. The packaging side of things became my kind of technical passion. But I mean, from a young age, I've always been the captain of the track team or the, you know, the head of any school organization I was a part of. So I always knew I, I wanted to be a leader. I think now, you know, being in that role, you, you learn so much about what different styles and brands of leadership is. I think, you know, to go back to your question about being the smartest in the room, I actually think that, you know, the CEO's job isn't to have all the answers. It's to create the culture where the answers emerge. And, you know, I've always wanted to be a leader. I've been passionate on that side, but I really think that the more, you know, more so than just having leadership pieces to you. It's about having that power to bring people together in that way. [00:07:31] Lindsey Dinneen: Yeah. That's a beautiful way to put it. And I actually would love to dive into this more because I know creating a really positive, good company culture is really important to you, and it's frankly, easy to get wrong, unintentionally-- sometimes maybe it just is what it is, but like sometimes it's not a desire to create it, but it happens. So I'm curious, how have you really intentionally cultivated your current company culture, and where did those lessons come from? [00:08:00] Sarah Ptach: Yeah. Deep question. You could answer that in a bunch of different ways and I could talk your ear off about lessons learned on that side. But I, I think the, you know, the most overlooked competitive advantage, both internally and externally is trust. Like the trust in your team to make decisions, the trust in your clients and even the FDA and your labs work. There's trust across it all. I think internally, from culture standpoint, it's have that trust in people and build, you know, people in a way that, that helps them feel most confident to, to make the decisions that they need to succeed. You know, when we first started talking you, you asked if I have any kind of lesson learned stories and some, I dunno, harsh realities per se. I think one of the more difficult kind of lessons that, that I learned in the course of just being a leader, is knowing when you have a passion for someone and what passions they might have. And I stayed that in the standpoint that I'm a huge believer in people. I want them to be like the greatest version of themselves, and I want them to dream big and go big and, you know, sometimes that's not always what people want for themselves too. And it's, it's a tough reality somewhat to to come to at times. But, you know, really finding what is the growth that people truly want. What is the environment that they want to live in, and how do you help foster something that, that meets the plethora of those ideals that you'll have across an organization is really important. But I think the, the culture I've worked really hard to foster at Canyon and frankly, my, my team fosters alongside me every day. This is by no means just a Sarah show on that piece. But it's a culture of trust, like I said, and it's a culture of transparency. I always like to tell my team, "you know, when I ask questions or probe I'm not trying to get an answer or I'm not trying to, you know, question your way of thinking. I'm trying to understand so that I can be at the same table that you're at and we're not, you know, talking oranges and apples and not realizing it." And so I really try to make sure we foster an environment where there's collaboration, there's trust to have that collaboration. There's trust to have challenges made of each other without it being an inflection of, you know, disliking someone. And then creating that opportunity to ask questions and always stay inquisitive in a way that's meant to greater raise everyone up together. [00:10:28] Lindsey Dinneen: Yeah, that's a wonderful culture that you're cultivating and I love that. But I think you hit on something really key amongst all of the really great points you made, but one of them that really stood out to me was, you talked about how it's not just the Sarah show in this way. It's a whole group effort. And I think that is a critical component that sometimes is forgotten. Like we sometimes think, you know, it's the leader's sort of job or role or just is. It is their leadership. That sort of filters down into the rest of the company and we think it's like a top down way of doing culture, but culture is about absolutely everybody involved in the company. So I'm curious, how do you empower your team members or, and, or when a new team member comes in, how do you communicate, "Hey, this is who we are, these are our values," and make sure that it is a good cultural fit too. [00:11:23] Sarah Ptach: Yeah. You know, we really at Canyon do a lot of things that are just small to, to reinforce and drive culture. We have these bracelets that you can earn, and what they mean is they're all of our company values and you can honor a fellow coworker for, for going above and beyond, or embodying teamwork or really showing integrity. And they get that read out in front of their whole department, and then they get a bracelet to wear proudly. So we do little things to to enhance our culture. And then there's the more macro level pieces, and I think having a baseline understanding of why we all show up to work every single day. You know, it really is to empower life changing medical innovation, and it's to ensure that all the products on the market are not gonna hurt somebody and they are going to, you know, do what they're meant to do in a positive way. You know, if we can all show up with the basis of "everything I do every day is for patient safety," then I think the getting on board with the culture is a lot easier if we all have that base, like regardless of how your day goes, regardless of your email inbox going crazy, we all agree that, you know, patient safety is what we're here to do. And you know, how we can have fun along the way, support each other, do teamwork is just gravy on top of that. So I'd say it's starting with culture that gets that base level item. And once you get that, everything else is just working better together. [00:12:48] Lindsey Dinneen: Yeah. Yes. And honestly, that's a great segue to my next question, but I was really-- I think you, again, honed in on something really critical and having everybody around a shared mission is so cool because that passion and that excitement and that " we're all in this together" and when disagreements or issues come up, which --we're human, they do-- then you can always go back to that shared mission and values of the work we're doing matters. We are all on the same side to provide value to our clients to ensure safety for our patients. So, I think that's a really key thing that you touched on there. Yeah. [00:13:33] Sarah Ptach: Don't get me wrong. I mean, it's a difficult thing to, you know, to keep going on teams. We, Canyon, we did two acquisitions this year. And with that comes a lot of combining cultures, changing culture together, all getting on the same page. And it's not easy, bumps along the road, you know, I think showing that we're all on the same page and working and rowing in the same direction is a conversation I have every single week. And so it's something you can keep reinforcing. And I think it's stacking bricks. You don't just have a house, you gotta continually stack bricks on it. And everyone needs to be involved in saying, "yeah, I wanna be a part of this team and I wanna be a part of this shared mission." And it doesn't build itself overnight. [00:14:19] Lindsey Dinneen: Yeah, absolutely. So speaking and then mentioning back to that segue, 'cause I just didn't ask the question, but can you share more about Canyon Labs and the incredible work that your company is doing for this industry? [00:14:34] Sarah Ptach: Yeah. Yeah. So like I said we're a full service contract testing and consulting firm within the medical device and pharmaceutical space. You know, a lot of the work we're doing is to help a lot of medical devices and drugs in their validation stage. So, you know, we're working through anything from, you know, designing your package to helping your sterilization strategy. You know, sterilization has been something I talked to, I've spoken on a lot this year. You know, it's a hot topic item in the industry. It's something that a lot of people are dealing with 'cause it has EPA implications as well as now tariffs affecting it as well as supply chain issues within it. So I'd say that's a division I talk to a lot and we help a lot of people navigate those. But the underlying whole piece of Canyon is being that trusted lab partner and we're really trying to raise the standard of service in this industry. You know, I came into Canyon being on the other side of the table and sending samples off to get biocom tested or to go through their sterilization validation. And, you know, for me it was this baby I was sending off to be tested and I don't think I was always met with the best customer service or the best accessible expertise when I needed it. And so we, when we built Canyon, we really built it to, to change that. You know, I want our clients to feel like we're one phone call away for any question that they have. You know, we're not just gonna send them their samples back, say, "sorry, it failed. Let us know when you're ready to give us another PO." That, that transactional relationship is, it's a currency that I don't wanna participate in. And so we really saw it after changing that in the industry. [00:16:16] Lindsey Dinneen: Yeah. Excellent. Well, yeah and I love the fact that you were on that flip side and it could bring such a valuable perspective to the company and go, "okay, here's some lessons learned." You know, and you're always gonna get a mix of it, right? You're gonna get like, "Ooh, I don't know if this is how it should be or needs to be," and you're gonna go, "oh, but here's something that they did excellently." So to bring that very valuable perspective is really cool. [00:16:40] Sarah Ptach: Yeah it's been fun. It's you know, in Canyon's infancy a couple years ago, we had the opportunity to come together with a lot of people from different experiences on our leadership team, and so it's-- as long as we all have the baseline humility to say "the way I did it in the past is not necessarily correct," you know, we could all come together and say, "here's what I did, here's what I did, here's what I did. Okay, let's pick the best of all worlds." So it it was a cool opportunity to have a lot of people with a lot of past experience come to a table that was completely, even in that standpoint. [00:17:18] Lindsey Dinneen: Yeah. Excellent. So I know that you are-- well, okay, so I took a look at your LinkedIn profile and had a wonderful time learning a little bit more about you, but I know you are involved so much. Like you are just, I don't know if you sleep because... [00:17:35] Sarah Ptach: Sometimes. [00:17:36] Lindsey Dinneen: Yeah. But the, I especially noticed, you know, you're a founding board member for thePACKout and you've done you're involved in a lot of different boards and groups and you're, it seems like you're just, you know, volunteering as kind of your heart and soul and serving in that way. And so I was wondering if you could speak a little bit about those opportunities that you're with too. [00:17:55] Sarah Ptach: Yeah. I think, first and foremost, before any job or role or position I've ever held, I am baseline, a huge proponent of this industry. And, you know, going back to my original reason to be here, it was my dad having Parkinson's and Parkinson's doesn't have a lot of treatment at this point. And it was like, I hate that. So how do I participate in solving that? And I think being involved in the industry, the super cool part, especially about packaging, is there's so much room for improvement at this point. You know, a lot of the standards that we function off of, they are being improved on a yearly basis, but they weren't made that long ago. So the, you know, the baseline ground zero is not that long ago. And I mean, there's people in the industry that are still in the industry that were there when they made ISO 11607. So it's, you know, it's, it's got a lot of room for improvement. I love how much the industry is trying to go back to patients now, and, you know, we're not just trying to design packages or devices that work well for, you know, me, the manufacturer, or me, the physician, but instead it, you know, really does consider patient comfort, patient safety. So the, a lot of what you'll see of my involvement in the industry is related to patient facing parts of of standards. I'm part of the Kilmer Renovations and Packaging Group and specifically I lead the aseptic presentation group, which is meant to evaluate the way that healthcare technicians interact with packaging in a way to help reduce hospital acquired infections. You know, we used to only design packages as an engineer because it's the perfectly engineered package. And, you know, we didn't think about the nurse that's trying to open it and your perfectly engineered package is just way too hard for a nurse to open and the device goes flying across the room. So it you know, we, we weren't considering those things. So our group is trying to correlate opening methods with types of packages and designs of packages. And we're trying to prove that with the different opening techniques that they teach in school for your surgical techs, your nurses, what is the best way for these different packages so that we can make that training and that design fit in the best way possible for positive patient outcomes. So, it's, a lot of my industry involvement is passion based, but I'd also say that a lot of the industry problems they, they can't be solved by just one company and they can't be solved in a silo. So, you know, the only opportunity you get to get all these stakeholders at the same table are these industry groups. And it's unique, I think, to the medical device industry in general that a lot of us care beyond our day jobs. You know, it's like, "cool, this is my day job, but I genuinely, passionately care about the development of my industry. And so I'm willing to, you know, volunteer my personal time." And I see that across the board every day. And it's really cool. I mean, you have people who have huge jobs at, you know, Johnson and Bausch & Lomb and Medtronic, and they're, you know, they're still willing to put their personal time on the table to advance the industry. So, yeah, all my industry involvement's pretty passion based, but it's the medical device industry and medtech industry is one that's super unique. A lot of people feel that personal passion. [00:21:20] Lindsey Dinneen: Yeah, I couldn't agree more. And thank you for sharing a little bit more about your involvement and your passion for the industry. And I feel so similarly, I, you know, when I joined the industry now a few years ago, I remember having this just moment of getting to meet all these super cool, intelligent innovators that are just literally changing the world and thinking "how lucky am I to be here and play a small part in this big changing thing," and then getting to see exactly to your point, how passionate the people are in the industry and how it's not just a job, it's like a calling. [00:21:59] Sarah Ptach: Well, I think the difference is, you know, in, in medtech, the origin or margin for error is not just financial, it's human. So where you have, you know, maybe your traditional job, you know, the margin of error is a financial impact. You know, the margin of error for people in our industry is human impacts, and that can be positive and negative. So it's hopefully the passion to make those more positively. So. [00:22:24] Lindsey Dinneen: Yes, indeed. Yeah, so, you know, I love the impact your company is making and the industry itself, like you said, is just such a cool place to be, and I think it really does invite those kinds of passionate people who are willing to just kind of be evangelists in a way for the rest of the industry in some fashion and really moving things forward. But because of the impact that's made, I'm wondering are there any moments that really stand out to you as affirming that, "hey, I am in the right place at the right time, in the right industry." [00:22:57] Sarah Ptach: Yeah. I mean, I definitely have some stories where you've-- without disclosing the details of a client-- but you know, you've been part of a launch that you watched that device go change the industry. I was a part of a company that was launching a, it's basically a, an organ transplant way of improving on how organs make it from, you know, the donor to the recipient. And it has improved patient outcomes tenfold to what they used to be. It's made it so that you could take, say, subpar lungs that used to not be able to be donated. And because of this technology, now it can, 'cause it, it has a way of it staying more intact while being transported. And you know, you get involved in those projects and, you know, you might just be helping at a small portion of it, like the sterilization or the packaging or just the biocom testing. But, you know, you watch the outcomes of that and it's like, "wow. Like I, I did that." You know, I've talked to people that work in consumer product goods and, you know, their Super Bowl is seeing their package on the grocery store aisle. And, you know, my, my Super Bowl is seeing the product that you played a part in, reach the market and change the world. Like that's, it's so cool. And to your point before you, you get to be in the room with such cool, innovative, smart people that came up with that product. I am, I'm honored to be the lab testing that is that silent backbone of medical innovation. But to be, you know, that trusted partner to, to get them to the finish line is a, it's a unique feeling, but it's really cool when you get to see a product that you played part of either touch a family member. I've been in an operating room before where I was the one being operated on 'cause I tore my ACL or did something and all I'm doing is looking at all the packaging, like, "Ooh, I did that. I tested that." Such a cool experience. It's sometimes it can be concerning 'cause you're sitting there while your doctor's trying to tell you to just get ready for surgery and you're staring at all the packaging. But it's, it's an awesome round to be in. [00:25:02] Lindsey Dinneen: Oh my goodness. I love that story so much. Yes. I mean, I could see that I, and I've talked to other folks who have similar experiences where they're, you know, they're kind of going along, something happens, they end up needing medical attention, or a family member does, and they go into the, to the hospital and they're like, "oh. I worked on that device" or "Oh, I did the cybersecurity for this one" or whatever, and just like how cool of a just full circle moment is that, and getting to watch in real time and in real life the impact that your work does. That is a huge honor and gift. [00:25:34] Sarah Ptach: Yeah, I I really did tear my ACL and my, and I also broke my back at one point in time, but my back surgeon and I have a really cool relationship and I think it's half because I was probably the biggest pain in the butt patient, 'cause leading up to that surgery it was like, "what device is it? What's the sterilization modality? Tell me what testing they did on it." And I got very lucky. My, my surgeon, his name's Dr. Michael Glisi, he has played actually a big role in getting some better improved medical devices to market both with Globus and with Arthrex. And now he plays a role in training other surgeons on how to best use those medical devices and technology. But it was such a unique relationship to get with him 'cause he's uniquely involved in the industry. So I think he, he maybe tolerates my 9 billion questions better than the average surgeon that just wants to operate on you and see you off. But it was a cool experience to get to, to have that relationship with him now after surgery and watch the impact that, that he's making on the industry as a surgeon too. So I think all stakeholders in this industry hold different areas of importance too. [00:26:49] Lindsey Dinneen: Yeah, absolutely. Oh my goodness. Yes. And, yeah, I could talk about all of this for days and I'm loving this conversation, but I am gonna pivot it, just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want, could be within your industry, but it doesn't have to be at all. What would you choose to teach? [00:27:13] Sarah Ptach: Ooh, that's a good question. I do think I would teach it on people leadership. You know, I, i've been in a lot of different roles and scenarios of people, leadership, especially through acquisitions, seeing, you know, the good, bad and ugly of what other folks do. And I've been really fortunate to have a lot of different mentors in my career that took very different leadership strategies. And I'm by no means saying that I'm the perfect people leader, but I think-- I can tell you a lot of different options and why they do and don't work. So if I was to teach a masterclass it'd probably be in that and I'd be heavy on the transparent leadership side. I'd be heavy on fostering a culture of people that are comfortable talking about issues. And it's not a easy thing to balance, I think with also driving, you know, the work product of the business and the financial success of the business. But being able to marry that, to marry, you know, having a great people culture and having, you know, people that, that love being a part of your company. It, to me, it is the most important part of actually driving your financial success of your company too. And I don't think a lot of people correlate that. You know, they think "I'm the ultimate financial driven CEO. I am the gross margin king." And, you know, " I'm driving my shareholder value." But I really think that, while all that is important, it starts with the people and the more you can get people to care about what they're doing beyond just their job, the more that the natural effect is improved gross margin and better financials. So the masterclass I'd probably teach is how to combine positive people, environment, and culture with good company financial success. [00:29:07] Lindsey Dinneen: Ooh, okay. That's a very powerful masterclass I wanna go take so, so sign me up for that, for sure. That's incredible. Yeah. And you have so much advice and insight and I could just tell, like, again, we could probably talk about this for hours and be very happy, so, yeah, I love that. Okay, and then how do you wish to be remembered after you leave this world? [00:29:30] Sarah Ptach: Yeah. Someone that, that cared deeply about the industry and was willing to to give it my all. You know, you, you jokingly said, "when do you sleep?" I'd argue not a lot, but it's because I love it. Like it's 'cause I love what I'm doing and if that means I'm gonna sacrifice some sleep to make sure the thePACKout is an awesome conference or the, you know, KIPP aseptic presentation team has what we need to change a standard or Canyon, you know, do something better and greater, I'll do it all day long. So yeah, I'd like to be remembered as, at the end of the day, she just really cared. And she was in it 110% at all times. [00:30:12] Lindsey Dinneen: I love that. That's a beautiful legacy. Yes, absolutely. Okay, and then final question, what is one thing that makes you smile every time you see or think about it? [00:30:23] Sarah Ptach: Oh, I love that one. I think someone realizing that the solution to the problem that they came up with was truly right and the solution. And it's like you worked through it yourself. You made it through maybe the hard parts of that decision making, but then you executed and hot dang, it worked. Like that is such a cool experience, especially when it's someone's first time ever having like the leadership role of solving a problem or, you know, the project manager role of solving that problem. It's super cool 'cause you get to watch someone's thought process play out. You get to watch where they see the pros and cons of their decision or the faults that could occur. And then you get to watch 'em navigate that, and then it succeeds and it's like, "hot dang, you did it." It's great. I love that. So that's probably something that makes me smile the most is when someone sees, their true potential being achieved, and they get to see it in the form of something as tangible as solving a problem. [00:31:22] Lindsey Dinneen: That is awesome. I love that so much. Oh my goodness. Well, this has been such an amazing conversation. I'm so thankful for you and for you being willing to share some of your time with me and with our listeners. So thank you so much for all the work you do, and thank you for being in the industry, being passionate about this industry and for being a change maker too, in the way that, you know, companies can operate and be successful. And we don't have to think about it just in terms of financial success, but we talk about it in terms of cultural success too. And so, I just really appreciate your perspective, so thank you for all the hard work you're doing to change lives for a better world. [00:32:02] Sarah Ptach: Thank you. Yeah, thank you, Lindsey. And likewise what you do. It's awesome to see you highlighting some of the stories in the industry and bringing together really good conversations like this. So thank you. [00:32:11] Lindsey Dinneen: Awesome. And we are so honored to be making a donation as a thank you for your time today to the Michael J. Fox Foundation, which is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. So thank you for choosing that organization to support. Again, thank you so much and thank you also to our listeners for tuning in and if you're feeling as inspired as I am right now, I would love it if you would share this episode with a colleague or two and we'll catch you next time. [00:32:49] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.  

Description Join host and Digital Education Committee Member, Danesh Kella, MBBS, FHRS and his guests Ratika Parkash, MD, MS, FHRS and Prashanthan Sanders, MBBS, PhD, FHRS at HRX Live 2025 in Atlanta, for this exciting discussion. The PRAGUE-25 trial, published in JACC in 2025, compared catheter ablation with a program of lifestyle modification plus antiarrhythmic drugs in obese patients (BMI 30–40 kg/m2) with symptomatic atrial fibrillation. At 12 months, freedom from atrial fibrillation was significantly higher with ablation (73%) than with lifestyle modification + AADs (35%), despite the latter group achieving greater weight loss and metabolic improvement. The findings suggest that while aggressive risk-factor control improves overall health, catheter ablation remains more effective for rhythm control in this population.    Learning Objectives Describe the comparative effectiveness of catheter ablation versus lifestyle modification with antiarrhythmic drug therapy in obese patients with symptomatic atrial fibrillation. Discuss how weight reduction and risk-factor modification influence atrial fibrillation outcomes, while recognizing that catheter ablation provides superior rhythm control despite metabolic improvements achieved through lifestyle intervention.   Article Authors Pavel Osmancik, Tomas Roubicek, Stepan Havranek, Jan Chovancik, Veronika Bulkova, Dalibor Herman, Martin Matoulek, Vladimir Tuka, Ivan Ranic, Jana Hozmanova, Marek Hozman, Lucie Znojilova, Adam Latinak, Jan Pidhorodecky, Milan Dusik, Jan Simek, Otakar Jiravsky, Bogna Jiravska-Godula, Frantisek Lehar, Michal Cernosek, Zuzana Hejdukova, Hana Zelinkova, Jiri Jarkovsky, and Klara Benesova  Podcast Contributors Prashanthan Sanders, MBBS, PhD, FHRS Danesh Kella, MBBS, FHRS Ratika Parkash, MD, MS, FHRS    All relevant financial relationships have been mitigated. Host Disclosure(s): D. Kella •Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum  ​Contributor Disclosure(s):    R. Parkash •Research: Abbott, Medtronic, Novartis • Membership on Advisory Committees: Medtronic  P. Sanders •Membership on Advisory Committees: Medtronic PLC, Pacemate, CathRx, Boston Scientific, Abbott Medical • Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical  Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

The shift to outpatient surgery is transforming how care is delivered. In this episode, Dr. Adam Thaler, Medical Director at Summit Health, discusses leading a urology-focused ambulatory surgery center and the rapid growth of outpatient procedures. He explains why airway management is the cornerstone of patient safety in ASCs and why he relies on video laryngoscopy, particularly the McGrath MAC, for every case. Dr. Thaler highlights the clinical, financial, and operational benefits of this technology, including reduced complications, improved efficiency, and enhanced patient experience. He also shares advice for ASC leaders on embracing innovation, doing their own research, and treating every patient with the same high standard of care. Tune in to hear how Dr. Thaler is shaping the future of outpatient surgery! Resources: Connect with and follow Dr. Adam Thaler on LinkedIn. Follow Summit Health on LinkedIn and explore their website! Check out Dr. Adam Thaler's Medtronic blog on How the intubation tools you choose can affect your facility's costs and more! References: Leifer S, Choi SW, AsanatiK, YentisSM. Upper limb disorders in anaesthetists-a survey of Association of Anaesthetistsmembers. Anaesthesia. 2019;74(3):285-291. doi:10.1111/anae.14446 Kriege M, Noppens R, TurkstraT, et al. A multicentrer randomized controlled trial of the McGrath MAC video laryngoscope versus conventional laryngoscopy. Anaesthesia. 2023;78(6):722-729. Zhang J, Jiang W, Urdaneta F. Economic analysis of the use of video laryngoscopy versus direct laryngoscopy in the surgical setting. Journal of Comparative Effectiveness Research. 2021;10(10):831-844. doi:https://doi.org/10.2217/cer-2021-0068 Nørskov AK, Rosenstock CV, Wetterslev J, Astrup G, Afshari A, Lundstrøm LH. Diagnostic accuracy of anaesthesiologists' prediction of difficult airway management in daily clinical practice: a cohort study of 188,064 patients registered in the Danish Anaesthesia Database. Anaesthesia. 2015;70(3):272-281. Kleine-Brueggeney M, Greif R, Schoettker P, Savoldelli GL, Nabecker S, Theiler LG. Evaluation of six video laryngoscopes in 720 patients with a simulated difficult airway: a multicentre randomized controlled trial. Br J Anaesth. 2016;116(5):670-9. Thaler A, Mohamod D, Toron A, Torjman MC. Cost comparison of 2 video laryngoscopes in a large academic center. Journal of Clinical Outcomes Management. 2021 July;28(4):174-179. Moucharite MA, et al. Factors and economic outcomes associated with documented difficult intubation in the United States. Clinicoecon Outcomes Res. 2021;13:227–239. Gaszyński T. Comparison of the glottic view during video-intubation in super obese patients: a series of cases. Ther Clin Risk Manag. 2016;12:1677–1682. Alvis BD, Hester D, Watson D, Higgins M, St Jacques P. Randomized controlled trial comparing the McGRATH™ MAC video laryngoscope with the King Vision video laryngoscope in adult patients. Minerva Anestesiol. 2016;82(1):30–35.

In this episode of Medsider Radio, we sat down with Tim Gleeson, CEO of BRIJ Medical, a company rethinking one of the oldest procedures in medicine — surgical wound closure.BRIJ's Brijjit Force Modulating Tissue Bridge is a small, non-invasive clip designed to redistribute tension across incisions, helping wounds heal with fewer complications and smaller scars.An accomplished entrepreneur and investor, Tim also founded and led Novasyte Health through its acquisition by IQVIA and later launched VIDANT Capital. A former Medtronic executive, Tim brings global experience and a lifelong passion for building impactful medtech ventures.In this interview, Tim shares why the biggest opportunities often hide in “boring” markets, how focusing on physician champions and patient psychology drives commercial traction, and why the best fundraisers plan for twice the time and four times the cost.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Gleeson.

Stephen Grootes speaks to Peter Mehlape, Managing Director at Medtronic and co-author of Winning in Africa – Your Next 8 Moves to Business Success in Africa. In the book, co-written with Professor Adrian Saville and Shameel Joosub, CEO of Vodacom Group, Mehlape shares practical insights on leadership, innovation, and what it takes to thrive in Africa’s dynamic business landscape The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

I will provide a comprehensive guide for investors so you can assess the performance of your current financial advisor... including communication skills and fee structure. I'll also outline the necessary steps for a smooth and compliant transition to a new wealth management professional. Today's Stocks & Topics: Cameco Corporation (CCJ), Market Wrap, Medtronic plc (MDT), When and How to Change Financial Advisors, American Financial Group, Inc. (AFG), Meta Platforms, Inc. (META), Volatility, Vale S.A. (VALE), Teleflex Incorporated (TFX), Spending, Apple Inc. (AAPL), Gold.Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out Progressive: https://www.progressive.com* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

 Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions. Wase explains, "So yes, pacemakers have been around for about seventy years. They've been helping people save lives, live fuller lives, and improve quality of life for that whole time. But you know, if you think about the history of a pacemaker, a pacemaker is a computer inside a little box that's implanted in the body. And like any computer, a computer from 70 years ago and a computer from today are very different. You know, 70 years ago, a pacemaker would've been about the size of a hockey puck, but even a little bit thicker. And nowadays, pacemakers are not much bigger than a couple of silver dollars stacked together. So we've made really big advances."   "When you had those hockey puck-sized pacemakers or even modern-sized pacemakers, there's no place in the heart for it. And so they end up in the chest, and then there's a wire called the lead that goes down through the veins into the heart, and that's where the electricity gets delivered down to make the heartbeat. And that's also where the heart's electricity comes back up, so the pacemaker can know what's wrong. As we have pacemakers smaller and smaller, though, we suddenly reach a point where a radical downsizing is a possibility. And again, leveraging the computer technology of the world, getting a pacemaker inside the heart instead of in the chest."   #Medtronic #CardiacCare #Pacemaker #LeadlessPacemaker #Micra #Cardiologists #HeartHealth #Innovation medtronic.com Download the transcript here   

 Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions. Wase explains, "So yes, pacemakers have been around for about seventy years. They've been helping people save lives, live fuller lives, and improve quality of life for that whole time. But you know, if you think about the history of a pacemaker, a pacemaker is a computer inside a little box that's implanted in the body. And like any computer, a computer from 70 years ago and a computer from today are very different. You know, 70 years ago, a pacemaker would've been about the size of a hockey puck, but even a little bit thicker. And nowadays, pacemakers are not much bigger than a couple of silver dollars stacked together. So we've made really big advances."   "When you had those hockey puck-sized pacemakers or even modern-sized pacemakers, there's no place in the heart for it. And so they end up in the chest, and then there's a wire called the lead that goes down through the veins into the heart, and that's where the electricity gets delivered down to make the heartbeat. And that's also where the heart's electricity comes back up, so the pacemaker can know what's wrong. As we have pacemakers smaller and smaller, though, we suddenly reach a point where a radical downsizing is a possibility. And again, leveraging the computer technology of the world, getting a pacemaker inside the heart instead of in the chest."   #Medtronic #CardiacCare #Pacemaker #LeadlessPacemaker #Micra #Cardiologists #HeartHealth #Innovation medtronic.com Listen to the podcast here   

Join host and HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH and her guests Jerome Kalifa, MD and Paul C. Zei, MD, PhD, FHRS as they discuss this article at HRX 2025 in Atlanta. The RESTART trial is an international, multicenter, non-randomized interventional study designed to assess whether using Volta Medical's AI-assisted algorithm to identify and ablate dispersed electrograms (EGMs) in addition to doing repeat pulmonary vein isolation can improve outcomes in patients whose atrial fibrillation recurred after previous ablations.The main goal is to see the proportion of patients who are free from AF twelve months after the repeat procedure (without antiarrhythmic drugs), and the trial contains about 92 patients.   Learning Objective Describe the design and purpose of the RESTART trial, including how the use of AI-guided identification and ablation of dispersed electrograms aims to improve outcomes for patients undergoing repeat ablation for recurrent atrial fibrillation.   Article Authors John D. Hummel Haroon Rachid Isabel Deisenhofer Paul C. Zei Gustavo Morales Jerome Horvilleur Stavros Mountantonakis Jean-Paul Albenque Devi G. Nair Benjamin D'Souza Smit C. Vasaiwala Tom De Potter Daniel H. Cooper Mark Metzl Adi Lador Anthony R. Magnano Alexandru B. Chicos Joshua R. Silverstein Daniel Guerrero Shirley Beguin Anas El-Benna Sabine Lotteau Marie-Sophie Nguyen-Tu Paola Milpied Jerome Kalifa Bradley P. Knight Dhanunjaya R. Lakkireddy Podcast Contributors Jerome Kalifa, MD Paul C. Zei, MD, PhD, FHRS Tina Baykaner, MD, MPH   All relevant financial relationships have been mitigated. Host Disclosure(s): T. Baykaner  •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific •Research: NIH ​Contributor Disclosure(s):    J. Kalifa: •Stock Options, Privately Held: Volta Medical P. Zei•Research: Biosense Webster, Inc. •Speaking/Teaching/Consulting: Biosense Webster, Inc., Varian Medical Systems, Abbott Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

In this episode of Your Diabetes Insider Podcast, Ben breaks down everything you need to know about insulin pumps - what's out there, how they work, and whether switching from injections is worth it. He covers the pros and cons of top options like Omnipod, Tandem, and Medtronic, shares real talk on convenience vs. reliability, and gives tips for figuring out which system fits your lifestyle best. If you've ever wondered, “Should I get a pump—or stick with shots?” this episode will help you decide. Want the best blood sugars you've ever had while enjoying great food? Peep this: https://www.yourdiabetesinsider.com/coaching   RESOURCES: Download these FREE guides that will help you on your diabetes, nutrition, and exercise journey! https://www.yourdiabetesinsider.com/free-stuff Watch my food breakdowns here → https://www.youtube.com/@yourdiabetesinsider   LET'S TALK! Instagram: @manoftzeel Tiktok: @manoftzeel

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Bill George is a celebrated leader who served as Chair and CEO of Medtronic, the world's leading medical technology company. He is an executive fellow at Harvard Business School, where he has taught leadership since 2004, and is the bestselling author of many books, including Discover Your True North. Bill also served as a director at Goldman Sachs, ExxonMobil, Novartis, Target, the Mayo Clinic, and World Economic Forum USA. In this episode of ⁠the Elevate Podcast⁠, Bill joins host Robert Glazer to discuss his leadership career, the importance of purpose-driven leadership, and more. To learn more about core values, check out The Compass Within. Thank you to the sponsors of The Elevate Podcast Mizzen & Main: ⁠⁠mizzenandmain.com⁠⁠ (Promo Code: elevate20) Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠masterclass.com/elevate⁠⁠ Found: ⁠⁠found.com/elevate Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week on Diabetes Connections.. Medtronic is making some big moves.. from new sensors, to spinning off the diabetes division.  Dr. Jen McVean, medical affairs director at Medtronic's diabetes business. Dr. McVean lives with type 1 and has a real passion for better access and better outcomes using technology. We talk about their latest real-world studies, questions doctors ask about these systems, the new sensors that are now available and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our last episode with Medtronic about their upcoming products and partnerships here (from May 2025) More about Medtronic's new Instinct sensor here More from Medtronic about the news here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

What really makes company culture crack as you scale from 10 to 30+ people? In this candid conversation, Aaron Schmookler (co-founder of The Yes Works) sits down with Àlex Rodríguez Bacardit (CEO, MarsBased) to unpack the patterns they have seen across startups and mid-size teams, remote and on-site.We dive into: preventing culture erosion during hypergrowth, why manager span of control matters, how to sell services without hard selling, practical leadership habits (Be Obvious), and the realities of building trust in distributed teams. Real stories touch on TextExpander, Medtronic, and SOG Knives, with step-by-step ideas you can apply tomorrow.If you lead a team, sell B2B services, or you are scaling a product org, this episode gives you actionable frameworks for structure, communication, and conflict, without the fluff.Support the show

Do you want to get into Medical Device Sales?? If so → https://www.newtomedicaldevicesales.comToday we have the pleasure of having Mr. Justin Marshall who has been in the Medical Device Industry for 15+ years. He has been a top performer and has worked at some of the largest medical device companies. Today he shares his story on how he broke into the industry as well as how he has been successful during that time

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

Do you want to get into Medical Device Sales?? If so → https://www.newtomedicaldevicesales.comToday we have the pleasure of having Mr. Justin Marshall who has been in the Medical Device Industry for 15+ years. He has been a top performer and has worked at some of the largest medical device companies. Today he shares his story on how he broke into the industry as well as how he has been successful during that time

In this week's episode, we revisit our interview with Shawn McCormick. Shawn has 30 years of financial expertise and operational experience in the medical device and life sciences industry. Most recently, he was the Chief Financial Officer of Aldevron, a private equity-backed CDMO. Shawn joined Aldevron in 2020 and remained until February 2022, following the sale of the company to Danaher, Inc. in 2021. He served as the Chief Financial Officer of Tornier N.V. and Tornier, Inc. from September 2012 until the completion of the merger with Wright Medical in October 2015. He also served as Tornier's Principal Accounting Officer. Mr. McCormick served as Chief Operating Officer of Lutonix Inc. from April 2011 to February 2012, when Lutonix was sold to C.R.Bard.  He served as Chief Financial Officer and Senior Vice President of ev3, Inc. from January 2009 to July 2010 and as its Principal Accounting Officer. ev3 was sold to Covidien in July 2010. Mr. McCormick held various positions of increasing responsibility at Medtronic, Inc. from 1992 to 2009, including Vice President of Corporate Development from May 2008 to January 2009 and Vice President of Finance for the Spinal, Navigation, and ENT business from 2002 to 2007.  He has been a Director of Nevro Corp. since September 2014 and Inspire Medical Systems Inc. since January 2017. He also served on the board of Surmodics, Inc from December 2015 to December 2020 and the board of Entellus Medical from December 2014 to February 2018, when Entellus was sold to Stryker. Mr. McCormick serves as the Audit Committee Chair for both Nevro and Inspire and previously for Entellus. He also served as a Surmodics' audit committee and governance and nominating committee member. Mr. McCormick served on the board of LANX from August 2010 to November 2013, serving on the Compensation Committee and Audit Committee before LANX was sold to Biomet in November 2013.  Mr. McCormick is a Certified Public Accountant (non-active license). He holds a B.S. in Accounting from Arizona State University and an M.B.A. from the University of Minnesota's Carlson School of Management. 

In this episode of Medsider Radio, we sat down with Josh Vose, CEO of Tulavi Therapeutics.Tulavi is advancing hydrogel-based implants like the allay Hydrogel Cap, which is designed to optimize nerve injury recovery and reduce the risk of neuroma formation.Josh is a physician, engineer, and entrepreneur with more than 20 years of experience in medical devices. He has held leadership roles at Medtronic following its acquisition of PEAK Surgical and drove growth at startups including SIA Health, which he led through commercialization and acquisition by Integra LifeSciences.In this interview, Josh shares why defining the clinical problem with absolute clarity is the foundation of medtech success, and how leaning into the harder regulatory path can create lasting moats.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Josh Vose.

Are you a night owl or a morning lark?For many of us the traditional working day just doesn't suit our circadian rhythms. We're called into a meeting or slumped over a desk at 8am but hyper focused as we're about to leave the office and head home. What if work took our biological clocks into account?In this episode I am joined by Camilla Kring, author of Chrono leadership. We talk about the costs of rigidity in work patterns, and what it takes to develop smarter, more flexible arrangements.Camilla's ideas are revolutionary; she talks about taking the bias away from the 5am club and creating better conditions in the workplace for all. Surely that is something we would all want to get behind.So, when do you perform at your best during the day?“Synchronise your work, family, and biological rhythms for real performance.” - CamillaYou'll hear about:·      How circadian rhythms dictate our natural sleep and wake cycles.·      Why understanding your chronotype can enhance productivity.·      The fact most people are not morning persons, yet workplaces favour early risers.·      How living out of sync with your internal clock can harm health.·      Flexibility in work hours can lead to higher productivity and well-being.·      Trust in employees being crucial for implementing flexible work schedules.·      Why synchronising work and family rhythms can improve life quality. More about Camilla:Camilla Kring, as the founder of Super Navigators, has dedicated the last 20 years to helping individuals navigate their lives and organisations create flexible and inclusive work cultures that accommodate different chronotypes and family structures. She has worked across Europe, China, Latin America and the Middle East with companies including Abbott, Medtronic, Roche and Novo Nordisk.Camilla's insights have been featured in the New York Times, the BBC and the Guardian. She is the author of six books and a TEDx speaker. She holds a Master of Science in Engineering and a PhD in work-life balance from the Technical University of Denmark (DTU). Resources:• Profile: https://www.camillakring.com/about-camilla/ • Book - Chronoleadership: https://www.camillakring.com/books/ • Supernavigators services: https://www.supernavigators.com/   My resources:Try my High-stakes meetings toolkit (https://bit.ly/43cnhnQ) Take my Becoming a Strategic Leader course (https://bit.ly/3KJYDTj)Sign up to my Every Day is a Strategy Day newsletter (http://bit.ly/36WRpri) for modern mindsets and practices to help you get ahead.Subscribe to my YouTube channel (http://bit.ly/3cFGk1k) where you can watch the conversation.For more details about me:●      Services (https://rb.gy/ahlcuy) to CEOs, entrepreneurs and professionals.●      About me (https://rb.gy/dvmg9n) - my background, experience and philosophy.●      Examples of my writing https://rb.gy/jlbdds)●      Follow me and engage with me on LinkedIn (https://bit.ly/2Z2PexP)●      Follow me and engage with me on Twitter (https://bit.ly/36XavNI)

Are you considering expanding your IR practice into pain management services? Get the download from someone who's done it already. In this episode of BackTable MSK, Dr. Sean Maratto from Philadelphia's Jefferson Health Network is joined by guest Dr. Junjian Huang from Emory University School of Medicine to discuss the intricacies of building a pain management practice within the interventional radiology space. ---This podcast is supported by an educational grant from Medtronic.---SYNPOSISDr. Huang shares his career journey, highlighting his shift towards pain palliation. The conversation covers a range of topics including procedural insights, patient management strategies, navigating institutional politics, and future trends in orthopedic IR. Dr. Huang emphasizes the importance of balancing patient care with building robust referral networks, and shares valuable advice for budding interventional radiologists.---TIMESTAMPS00:00 - Introduction02:20 - What's Your Why? Why Pain Intervention? 12:52 - Building a Complex Pain Management Practice24:47 - Marketing a Service Line30:57 - Patient Impact from Pain Management Services39:53 - Recommendations and Indications for Cryoneurolysis and BVNA 45:36 - Post-Procedure Follow-up and Psychosomatic Pain Guidance52:35 - Insight to the Future of Interventional Pain and Final Thoughts---RESOURCESDr. Junjian Huang, MDhttps://med.emory.edu/directory/profile/?u=JHUAN22 Dr. Sean Maratto, MDhttps://www.jeffersonhealth.org/find-a-doctor/m/maratto-sean-a

Do you want to get into Medical Device Sales?? If so → https://www.newtomedicaldevicesales.comToday we have the pleasure of having Mr. James Watkins who went from being an Associate Sales Rep all the way a former Vice President at Medtronic. He goes into his journey on how he was able to break in and the journey it took to make it to VP

Do you want to get into Medical Device Sales?? If so → https://www.newtomedicaldevicesales.comToday we have the pleasure of having Mr. James Watkins who went from being an Associate Sales Rep all the way a former Vice President at Medtronic. He goes into his journey on how he was able to break in and the journey it took to make it to VP

This study examined outcomes of patients with atrial fibrillation treated with pulsed field ablation (PFA) and found a notably high incidence of phrenic nerve injury during the procedure. Most injuries were transient, but some persisted beyond the immediate peri-procedural period, raising concerns about long-term safety. The findings highlight the need for refined techniques and monitoring strategies to mitigate phrenic nerve injury risk with PFA. Please join host Michael S. Lloyd, MD, FHRS as he discusses the finding of this study with his guests Andrea M. Russo, MD, FHRS and Birju Rao, MD, Msci in Atlanta at the HRX Live 2025 conference. Learning Objective:  Examine outcomes of patients with atrial fibrillation treated with pulsed field ablation (PFA). Article AuthorsLouis Chéhirlian, MD, Linda Koutbi, MD, Julien Mancini, MD, PhD, Jérôme Hourdain, MD, Robin Richard-Vitton, MD, Marie Wilkin, MD, Jean-Claude Deharo, MD, Baptiste Maille, MD, PhD, Frédéric Franceschi, MD, PhD  Podcast Contributors Michael S. Lloyd, MD, FHRS | Emory University Andrea M. Russo, MD, FHRS | Cooper University Health Care Birju Rao, MD, Msci | Emory University Contributor Disclosure(s): M. Lloyd:   •Membership on Advisory Committees: Boston Scientific •Speaking/Teaching/Consulting: Medtronic, ArgaMedtech, Circa Scientific   B. Rao •Nothing relevant to disclose. A. Russo: •Honoraria/Speaking/Consulting: Pacemate, Abbott Medical, Medtronic, BiosenseWebster, Inc., AtriCure, Inc., Bayer Healthcare Pharmaceuticals, Boston Scientific •Research: Medtronic, Boston Scientific, Abbott, Bayer Healthcare Pharmaceuticals •Royalty Income: UpToDate,Inc. •Fellowship Support: Medtronic, Inc.   Bonus video of this episode, recorded at HRX Live 2025 in Atalnta, can be found on HRS365 and the HRX Innovation Hub.

In this episode of the Investing in Integrity podcast, Ross Overline, CEO and co-founder of Scholars of Finance, welcomes Bill George, Legendary Business leader and former CEO of Medtronic, Harvard Business School professor, and board member at Goldman Sachs, for a candid conversation on authentic leadership in finance. Drawing on decades of executive and boardroom experience, Bill highlights why integrity, emotional intelligence, and purpose-driven decision-making are vital in today's financial landscape. Together, they discuss strategies for combating greed, building sustainable long-term value, and staying true to one's moral compass even in high-stakes environments. The discussion also explores navigating ethical challenges in the age of AI and ensuring finance remains a force for good. Whether you're an aspiring finance professional or a seasoned investor, this episode offers valuable insights on leading with character and transforming business through values-based leadership.Meet Bill George:Bill George is an Executive Education Fellow at Harvard Business School and former chairman and CEO of Medtronic, where he led from 1991 to 2001. Earlier in his career, he held senior roles at Honeywell, Litton Industries, and the U.S. Department of Defense. A prolific author, Bill has written several influential books on authentic leadership, including True North. He has served on the boards of Goldman Sachs, ExxonMobil, Novartis, Target, and the Mayo Clinic. Recognised with honors such as the Bower Award for Business Leadership, Bill is widely respected for advancing values-driven leadership in business and society.

In this episode of Medsider Radio, we sat down with Ahmed Elmouelhi, CEO of TRiCares.  TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men's health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Ahmed Elmouelhi.

In this episode of CAREER-VIEW MIRROR, we're celebrating the career to date of Richard Savoie.Richard is the co-founder and CEO of Adiona, which uses AI to power millions of efficient, lowest-carbon deliveries around the world for brands such as Coca-Cola and Amazon. He's a sought-after speaker and thought leader on transport, mobility, and AI.His career has taken him from New Hampshire to Boston, and eventually to Sydney, Australia, through roles at EMC, Smiths Medical, and Medtronic. Along the way, he's gained experience across engineering, medical devices, and entrepreneurship — building resilience, adaptability, and the insight to eventually launch his own business in sustainable technology.In our conversation, we talk about Richard's early years in Nashua, New Hampshire, where family challenges and early responsibilities shaped his determination. He shares how severe asthma inspired him first toward medicine, then pivoted him into engineering after falling in love with physics.We follow his path through Northeastern University, internships with Panametrics and EMC, and his transition into medical devices with Smiths Medical and Covidien. He reflects on career setbacks during the financial crisis, lessons from mentors, and the importance of empathy and relationships in leadership.We also talk about his relocation to Australia, his experience running a small medical device company, and the difficult decision to leave after equity disagreements — a setback that ultimately led him into entrepreneurship. Richard describes how Adiona's optimisation technology, developed through a partnership with Coca-Cola, delivered dramatic reductions in emissions and on-road time, and how branding, support structures, and resilience are critical to startup success.Connect with RichardLinkedIn:  https://www.linkedin.com/in/richsavoie/Website: https://www.adionatech.com/About AndyI'm a business leader, coach, and the creator of the Fulfilling Performance framework—designed to help people bring more of themselves to what they do and experience greater fulfilment and performance as a result.Over the past 25+ years, I've led and developed businesses including Alphabet UK, BMW Financial Services in the UK, Singapore, and New Zealand, and Tesla Financial Services UK. Alongside this, I've coached individuals and facilitated leadership development programmes in 17 countries across Asia, Europe, and North America.In 2016, I founded Aquilae to support leaders and teams in the mobility sector and beyond. Through workshops, coaching, and peer mentoring, we enable high performance that's also fulfilling—for individuals, teams, and organisations.Learn more about Fulfilling PerformanceCheck out Release the Handbrake! The Fulfilling Performance HubConnect with AndyLinkedIn: Andy FollowsEmail: cvm@aquilae.co.ukJoin a peer mentoring team: Aquilae AcademyThank you to our sponsors:ASKE ConsultingEmail: hello@askeconsulting.co.ukAquilaeEmail: cvm@aquilae.co.ukEpisode Directory on Instagram @careerviewmirror  If you enjoy listening to our guests career stories, please follow CAREER-VIEW MIRROR in your podcast app. Episode recorded on 09 September, 2025.

Part 2 of Eoin's chat with Jason Ziobrowski (Chef Jay Z).Today's guest brings flavor, passion, and purpose to everything he does. Jason Ziobrowski — or as many know him, Chef Jay-Z — has spent nearly two decades as a corporate R&D chef, creating recipes and nutrition programs for hospitals, patients, and communities. His mission? To influence people positively through food and to help change the American palate, one dish at a time.But behind the chef's coat is a deeply personal journey. After years of being told he was simply ‘pre-diabetic,' Jason was finally diagnosed in 2020 with type 1.5 diabetes. At the time, his fasting sugars were nearly 22.2mmol/L (400mg/dL), and his A1C hit 14.Instead of giving up, Jason took charge. He overhauled his lifestyle cold turkey, dropping his fasting sugars down into a healthy range and transforming not just his health, but his outlook on life.Today, Chef Jay-Z is thriving with type 1, using technology like the Medtronic pump, leaning on his family, and continuing to inspire others through food, education, and his own story of resilience. From hospital kitchens to his own blood sugar battles, Jason has learned that lifestyle change isn't just necessary — it can be one of the best things to ever happen to you.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Please join HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH, of Stanford University, as she is joined by Heart Rhythm Society President Mina K. Chung, MD, FHRS, of the Cleveland Clinic, and Konstantinos C. Siontis, MD, FHRS of the May Clinic. The three met up in Altanta at HRX 2025 for this stimulating coversation. This study evaluated whether artificial intelligence applied to single-lead ambulatory ECGs could predict imminent sustained ventricular arrhythmias. Using deep learning models, the researchers demonstrated that AI could identify subtle ECG features preceding arrhythmic events, enabling accurate short-term risk prediction. The findings suggest a potential role for AI-enhanced ECG monitoring to improve early detection and prevention of life-threatening ventricular arrhythmias. To view bonus video recorded LIVE at HRX 2025 in Atlanta, view this episode on Heart Rhythm 365 or the HRX Innovation Hub! Article Authors Laurent Fiorina ∙ Tanner Carbonati∙ Kumar Narayanan ∙ Jia Li ∙ Christine Henry ∙ Jagmeet Singh ∙ Eloi Marijon Read the Article: https://www.heartrhythmjournal.com/article/S1547-5271(23)02195-1/fulltext Podcast Contributors and Disclosures Tina Baykaner, MD, MPH | Stanford University Mina K. Chung, MD, FHRS | Cleveland Clinic Konstantinos C. Siontis, MD, FHRS | Mayo Clinic All relevant financial relationships have been mitigated. T. Baykaner:   •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific Research: NIH M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, MediasphereMedical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association K. Siontis: •Research: Anumana, Varian Medical Systems •Intellectual Property Right: Anumana •Speaking/Teaching/Consulting: EBAMedSA, AskBio

In today's episode Eoin chats with Jason Ziobrowski (Chef Jay Z).Today's guest brings flavor, passion, and purpose to everything he does. Jason Ziobrowski — or as many know him, Chef Jay-Z — has spent nearly two decades as a corporate R&D chef, creating recipes and nutrition programs for hospitals, patients, and communities. His mission? To influence people positively through food and to help change the American palate, one dish at a time.But behind the chef's coat is a deeply personal journey. After years of being told he was simply ‘pre-diabetic,' Jason was finally diagnosed in 2020 with type 1.5 diabetes. At the time, his fasting sugars were nearly 22.2mmol/L (400mg/dL), and his A1C hit 14.Instead of giving up, Jason took charge. He overhauled his lifestyle cold turkey, dropping his fasting sugars down into a healthy range and transforming not just his health, but his outlook on life.Today, Chef Jay-Z is thriving with type 1, using technology like the Medtronic pump, leaning on his family, and continuing to inspire others through food, education, and his own story of resilience. From hospital kitchens to his own blood sugar battles, Jason has learned that lifestyle change isn't just necessary — it can be one of the best things to ever happen to you.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

R Blank is the founder of Healthier Tech and the host of “The Healthier Tech Podcast”, available on iTunes, Spotify, and all major podcasting platforms.R has a long background in technology. Previously, R ran a software engineering firm in Los Angeles, producing enterprise-level solutions for blue-chip clients, including Medtronic, Apple, NBC, Toyota, Disney, Microsoft, the NFL, Ford, IKEA, and Mattel.In the past, he served on the faculty at the University of Southern California Viterbi School of Engineering, where he taught software engineering, as well as at the University of California, Santa Cruz.He has spoken at technology conferences around the world, including in the US, Canada, New Zealand, and the Netherlands, and he is the co-author of “AdvancED Flex Development” from Apress.He has an MBA from the UCLA Anderson School of Management and received his bachelor's degree, with honors, from Columbia University. He has also studied at Cambridge University in the UK, the University of Salamanca in Spain, and the Institute of Foreign Languages in Nizhny Novgorod, Russia.Shield Your Family from Hidden EMF Risks, check out R Blank's free guide by clicking on this link: https://shieldyourbody.com/empowered Connect with R Blank:Website: https://shieldyourbody.com/empowered Social Media: @shieldyourbody TurnKey Podcast Productions Important Links:Guest to Gold Video Series: www.TurnkeyPodcast.com/gold The Ultimate Podcast Launch Formula- www.TurnkeyPodcast.com/UPLFplusFREE workshop on how to "Be A Great Guest."Free E-Book 5 Ways to Make Money Podcasting at www.Turnkeypodcast.com/gift Ready to earn 6-figures with your podcast? See if you've got what it takes at TurnkeyPodcast.com/quizSales Training for Podcasters: https://podcasts.apple.com/us/podcast/sales-training-for-podcasters/id1540644376Nice Guys on Business: http://www.niceguysonbusiness.com/subscribe/The Turnkey Podcast: https://podcasts.apple.com/us/podcast/turnkey-podcast/id1485077152

In this episode, Kevin Kelleher (Director of Medical Affairs at Medtronic & founder of the Rural Health Technology Consortium) shares his journey from nurse to sales leader, and why passion, and not just money, must drive your career.Kevin's story really stuck with me. He went from nursing into sales, but what makes his perspective different is how he ties everything back to passion and purpose. He also opens up about what it's like serving rural communities, the push for more diversity in clinical research, and even how he balances leadership with family life. Honestly, it's one of those conversations that leaves you rethinking your life. From breaking into medical sales, building trust in rural healthcare, and tackling diversity in clinical research, to leadership, productivity, and family balance... Kevin brings powerful lessons you can apply today.

Join Hannah Campbell, program manager for AORN's Surgical Safety Award Programs, in this episode of Periop Talk. Hannah interviews Marci Kling, a perioperative nurse educator at Emerson Health, who spearheaded the hospital's successful initiative to earn the Go Clear Award for smoke evacuation. Discover how Emerson Health transitioned to a smoke-free environment through grassroots efforts, leadership support, and staff education, leading to significant improvements in patient and staff safety. Learn More about how you can leverage AORN's Center of Excellence in Surgical Safety: Smoke Evacuation in your facility: https://www.aorn.org/education/education-for-facilities/surgical-safety-center-of-excellence/go-clear-awardsThis evidence-based program is made possible by Medtronic through the AORN Foundation.Support the showWelcome to the Periop Talk—your go-to podcast series where we examine the world of perioperative nursing.Episode after episode, we're bringing you professional tips, clinical wisdom, and personal stories that'll make you feel like you're chatting with your work BFFs. Curious about the latest surgical techniques? We got you. Wondering how to navigate the challenges of the periop journey? We're here for that too.Our podcast series isn't just about sharing information; it's about building a community. Meet the people behind the masks, hear their journeys, and join the rotation of periop professionals making a difference. From students and new nurses to seasoned pros, we've got content for every stage of your perioperative practice.Periop Talk is your peek behind the red line to the world of perioperative nursing. It's not just about the OR – it's about the heart and soul of healthcare. Let's scrub in and start making surgery safer, one podcast at a time.Want us at: (1) Periop Talk vlog - YouTube

Jennifer Chavez joins the show to share her unique path through medical sales — from breaking in as a remote sales rep at Medtronic, to driving strategy as a vascular account executive at Cook Medical, to now leading her own consulting firm helping medtech companies build sales teams and win hard-to-access accounts. She pulls back the curtain on what it's really like to succeed in roles that go beyond the OR. You'll hear how remote sales reps add value, why key account roles require a different skill set, and what it takes to balance strategic storytelling with on-the-ground sales execution. Jennifer also opens up about life as a single mom building a career in this demanding industry, the mindset shifts that fueled her success, and why betting on herself to launch a business was the natural next step. If you've ever wondered how to climb the ladder in medical sales without following the traditional rep-to-manager path, or what it takes to thrive in high-level strategic roles, this conversation is packed with insights you won't want to miss.   Connect with Jennifer: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

Derek interviews NY Times best selling author, Brian Moran. Brian Moran has over thirty years of expertise as a CEO, corporate executive, entrepreneur, consultant and coach. His background as a corporate executive combined with his experience as an entrepreneur positions him with a unique skill set to help individuals and organizations grow and prosper.Brian's corporate experience includes management and executive positions with UPS, PepsiCo, and Northern Automotive. As an entrepreneur he has personally launched and led successful businesses and been instrumental in the success of many others. In addition, he has consulted for dozens of world-class companies including Coldwell Banker, Mass Mutual, Medtronic, New York Life, and Tiffany & Co.Brian is a recognized expert in the field of leadership and execution. His realization that most people don't lack ideas but struggle with effective implementation led him to the development of The 12 Week Year. In addition to his books, Brian has been published in many of the leading business journals and magazines. He is a sought after speaker, educating and inspiring thousands each year.He is a visionary with a passion for helping others go beyond what they think they are capable of and achieve more than they ever thought possible. His greatest strength might be his ability to take success principles and strategies and help others apply them in a way that is powerful and effective, and gets results.Learn more at: https://12weekyear.com/Business Leadership Series Intro and Outro music provided by Just Off Turner: https://music.apple.com/za/album/the-long-walk-back/268386576

Carl Quintanilla, David Faber and Mike Santoli led off the show with developments regarding Intel: Softbank investing $2 billion in the company, as the Trump Administration reportedly weighs taking a 10% stake in the chipmaker. Commerce Secretary Howard Lutnick joined the program and discussed a potential government investment in Intel. Also in focus: Home Depot's quarterly miss, Palo Alto Networks sharesjump on earnings, Nexstar to buy rival TV stations operator Tegna, the "SPAC king," Medtronic and activism, why one particular stock is plummeting 40%. Squawk on the Street Disclaimer